241 related articles for article (PubMed ID: 30811511)
1. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
2. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
Geng X; Liu Y; Diersch S; Kotzsch M; Grill S; Weichert W; Kiechle M; Magdolen V; Dorn J
PLoS One; 2017; 12(11):e0186847. PubMed ID: 29095848
[TBL] [Abstract][Full Text] [Related]
6. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients.
Obiezu CV; Scorilas A; Katsaros D; Massobrio M; Yousef GM; Fracchioli S; Rigault de la Longrais IA; Arisio R; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2380-6. PubMed ID: 11489816
[TBL] [Abstract][Full Text] [Related]
7. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
Wang P; Magdolen V; Seidl C; Dorn J; Drecoll E; Kotzsch M; Yang F; Schmitt M; Schilling O; Rockstroh A; Clements JA; Loessner D
Br J Cancer; 2018 Oct; 119(7):1-9. PubMed ID: 30287916
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
9. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
Lokman NA; Pyragius CE; Ruszkiewicz A; Oehler MK; Ricciardelli C
Transl Res; 2016 May; 171():83-95.e1-2. PubMed ID: 26925708
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.
Ahmed N; Dorn J; Napieralski R; Drecoll E; Kotzsch M; Goettig P; Zein E; Avril S; Kiechle M; Diamandis EP; Schmitt M; Magdolen V
Biol Chem; 2016 Dec; 397(12):1265-1276. PubMed ID: 27483364
[TBL] [Abstract][Full Text] [Related]
11. Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
Foteinou E; Kontos CK; Giotakis AI; Scorilas A
Biol Chem; 2014 Sep; 395(9):1051-62. PubMed ID: 24854539
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
13. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
14. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
[TBL] [Abstract][Full Text] [Related]
15. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
17. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.
Kyriakopoulou LG; Yousef GM; Scorilas A; Katsaros D; Massobrio M; Fracchioli S; Diamandis EP
Clin Biochem; 2003 Mar; 36(2):135-43. PubMed ID: 12633763
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
